All Categories
Conjugate Vaccine

Conjugate Vaccine

Home >  Vaccine  >  Non-recombinant DNA Technology  >  Conjugate Vaccine

Conjugate Vaccines

Conjugate vaccines are formed by coupling the key antigen (like bacteria polysaccharide, tumor antigen) with a carrier protein such as toxoid and virus-like particle (VLP). The former one is taken as the weak antigen and the later one isstrong antigen to elicite a stronger immunological response to the weak antigen. 

Yaohai Bio-Pharma has more than a decade of microbial CDMO experience. Based on the GMP workshop with Biosafety Level 1 (BSL-1) and Biosafety Level 2 (BSL-2), we provide a one-stop solution for microbial strain development, fermentation, extraction, purification of microbial-produced antigens and carrier proteins, as well as chemically coupling, aseptic filling of conjugate vaccine.

According to the customized needs of customers, we provide customers with intermediates, vaccine drug substance (DS, API) or drug produce (DP) that meet quality standards, as well as GMP production records and test reports.

List of Conjugate Vaccines

Haemophilus B (Hib), consisting Hib polysacchride and a carrier protein, is the most commonly used conjugate vaccine. Other conjugate vaccines were also approved against bacteria pathogens like Streptococcus pneumoniae and Neisseria meningitidis.

Diphtheria toxoid (DT), diphtheria CRM197, tetanus toxoid (TT), meningococcal outer membrane protein complex (OMPC) are widely used carrier proteins in approved conjugate vaccines.

Besides, other conjugate vaccines as prophylactic or therapeutic biologics are being researched in pre-clinical and clinical trials. 

Table 1. List of Approved Conjugate Vaccines

Brand Name

Generic Name

Carrier Protein

Company

Liquid PedvaxHIB

Haemophilus B Conjugate Vaccine

Meningococcal outer membrane protein complex (OMPC)

Merck, Merck Sharp & Dohme (MSD)

ActHIB

Haemophilus B Conjugate Vaccine

Tetanus Toxoid (TT)

Sanofi

Hiberix

Haemophilus B Conjugate Vaccine

Tetanus Toxoid (TT)

GlaxoSmithKline (GSK)

Menveo

Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Conjugate Vaccine

Diphtheria CRM197

GlaxoSmithKline (GSK)

Menactra

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Conjugate Vaccine

Diphtheria Toxoid (DT)

Sanofi

MenQuadfi

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine

Tetanus Toxoid (TT)

Sanofi

Prevnar 13

Pneumococcal 13-valent Conjugate Vaccine

Diphtheria CRM197

Pfizer, Wyeth 

Vaxneuvance

Pneumococcal 15-valent Conjugate Vaccine

Recombinant CRM197

Merck, Merck Sharp & Dohme (MSD)

Prevnar 20

Pneumococcal 20-valent Conjugate Vaccine

Diphtheria CRM197

Pfizer, Wyeth

Cimavax-EGF

Epidermal growth factor (EGF) cancer vaccine

Meningococcal P64k Protein

CIMAB

Related Service: Carrier Protein (Recombinant) or Carrier Protein (Extracted)
Our Deliverables

Grade

Deliverables

Specification

Applications

GMP, BSL-1/BSL-2

Intermediate substance

Microbial-produced antigen

Investigational new drug (IND),

Clinical trial authorisation (CTA),

Clinical trial supply,

Biologic license application (BLA),

Commercial supply

Microbial-produced carrier protein

Drug substance

Conjugate vaccine

Drug product

Vials (liquid)

Vials (lyophilized)

Other Dosage Forms

Get a Free Quote

Get in touch